Finance

Lists
Why is PYXS down 2,28%?
Dive Deeper
PYXS:NASDAQ
Pyxis Oncology Inc
2,14 USD
-2,28%
(-0,050) 1D
2,15 USD
+0,43% (+0,0092)
After hours
Closed: 2-окт., 16:00:00 GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for PYXS...
Open
2,21 USD
High
2,31 USD
Low
2,10 USD
Mkt. cap
178,49 млн
Avg. vol.
1,12 млн
Volume
2,00 млн
52-wk high
5,55 USD
52-wk low
1,03 USD
EPS
-1,40 USD
Beta
1,37
Shares outstanding
83,41 млн
No. of employees
56
Open
2,21 USD
High
2,31 USD
Low
2,10 USD
Mkt. cap
178,49 млн
Avg. vol.
1,12 млн
Volume
2,00 млн
52-wk high
5,55 USD
52-wk low
1,03 USD
EPS
-1,40 USD
Beta
1,37
Shares outstanding
83,41 млн
No. of employees
56
News stories
From web sources and news partners
About Pyxis Oncology Inc
CEO-
Employees56
Founded2018
HeadquartersБостон, Массачусетс, Америка Кошмо Штаттары
Sector-
Websitepyxisoncology.com
Analyst ratings
Based on 7 analysts giving stock ratings to PYXS in the past 3 months
Strong buy
Buy
6
Hold
1
Sell
0
12-month forecast
Based on 7 Wall Street analysts offering 12 month price targets for PYXS in the last 3 months.
Highest
Current 2,14 USD
19,00 USD (+787,85%)
Average
9,00 USD (+320,56%)
Lowest
6,00 USD (+180,37%)
Analyst
Recommendation
Action
Price target
Projected
Date
Swayampakula Ramakanth
H.C. Wainwright
Buy
Reiterated
8,00 USD
+273,8%
10/01/2026
Sam Slutsky
LifeSci Capital
Buy
Maintained
8,00 USD
+273,8%
09/26/2026
Andy Hsieh
William Blair
Hold
Reiterated
-
-
09/09/2026
Alexandra Ramsey
William Blair
Hold
Reiterated
-
-
09/09/2026
Derek Archila
Wells Fargo
Buy
Reiterated
19,00 USD
+787,9%
09/10/2026
Leonid Timashev
RBC Capital
Buy
Maintained
6,00 USD
+180,4%
09/09/2026
Stephen Willey
Stifel Nicolaus
Buy
Maintained
7,00 USD
+227,1%
08/17/2026
Robert Driscoll
Wedbush
Buy
Reiterated
6,00 USD
+180,4%
08/14/2026
Unknown Analyst
Guggenheim
Buy
Maintained
7,00 USD
+227,1%
06/29/2026
Last report
2026-ж., 13-авг.
Fiscal period
Q2 2026
EPS / Est. (USD)
-0,40 USD / -0,35 USD
-14,29%miss
Revenue / Est. (USD)
- / 22,22 миң
Fiscal Q2 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
2025-ж. сен.
2025-ж. дек.
2026-ж. мар.
2026-ж. июн.
Revenue
-
11,04 млн
-
-
Cost of goods sold
-
2,39 млн
-
-
Cost of revenue
-
2,39 млн
-
-
Research and development expenses
17,81 млн
21,71 млн
19,98 млн
16,06 млн
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
4,97 млн
4,54 млн
3,75 млн
9,54 млн
Operating expense
22,78 млн
26,25 млн
23,73 млн
25,60 млн
Total operating expenses
22,78 млн
28,64 млн
23,73 млн
25,60 млн
Operating income
-22,78 млн
-17,60 млн
-23,73 млн
-25,60 млн
Other non operating income
-
-
-
-
EBT including unusual items
-22,00 млн
-17,00 млн
-23,27 млн
-25,35 млн
EBT excluding unusual items
-22,00 млн
-17,00 млн
-23,27 млн
-25,35 млн
Income tax expense
-
1,10 млн
-
-
Effective tax rate
-
-6,49%
-
-
Other operating expenses
-
-
-
-
Net income
-22,00 млн
-18,11 млн
-23,27 млн
-25,35 млн
Net profit margin
-
-164,03%
-
-
Earnings per share
-0,35
-0,29
-0,37
-0,40
Interest and investment income
774,00 миң
600,00 миң
457,00 миң
255,00 миң
Interest expense
-
-
-
-
Net interest expenses
774,00 миң
600,00 миң
457,00 миң
255,00 миң
Depreciation and amortization charges
-
-
-
-
EBITDA
-22,25 млн
-14,71 млн
-23,27 млн
-25,30 млн
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google колдонмолору